相关实验视频
Updated: Jul 10, 2025
08:07
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
Published on: April 7, 2023
3.4K
在当前和前长期使用合成安卓类固醇类固醇的患者中出现严重的双腹肌心肌病
Rang Abdullah1,2,3, Astrid Bjørnebekk2, Lisa E Hauger2,4
1Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
European journal of preventive cardiology
|November 22, 2023
概括
长期使用类固醇-类固醇 (AAS) 会导致严重的双心室心肌病症和降低缩功能,即使在停止使用后. 这会影响举重运动员的心血管健康.
科学领域:
- 心脏病学 心脏病学
- 运动医学 运动医学
- 内分泌学 在内分泌学.
背景情况:
- 类固醇类固醇 (AAS) 是一种具有已知的心血管风险的增强性药物.
- 在运动员,特别是举重运动员中长期使用AAS,需要了解其对心脏结构和功能的影响.
- 之前的研究已经表明了潜在的不良心血管影响,但需要对现有和前用户的全面数据.
研究的目的:
- 为了研究长期使用合成类固醇 (AAS) 对举重运动员的心血管影响.
- 评估心肌功能,包括左心室和右心室功能,目前和前AAS用户.
- 为了确定AAS使用时间和剂量与心脏异常之间的相关性.
主要方法:
- 横截面研究比较了101名举重AAS使用者 (累计使用≥1年) 与71名举重对照者 (WLC).
- 利用临床数据和心声学来评估左心室质量指数 (LVMI),左心室喷射率 (LVEF) 和右心室全球纵向应变 (RVGLS).
- 分析了当前与以前的AAS用户,并将AAS暴露与心脏参数相关联.
主要成果:
- 与WLC相比,AAS使用者表现出明显更高的LVMI,更低的LVEF,更糟糕的RVGLS和更高的缩血压.
- 当前和前AAS使用者均表现出病态的LVMI和LVEF,心肌功能严重降低的发病率相似 (LVEF ≤40%).
- 目前使用者的终身AAS剂量与减少的LVEF和RVGLS相关;AAS使用史是减少LVEF的最强预测因素.
结论:
- 长期使用类固醇类固醇 (AAS) 的人会出现严重的双心室心肌病.
- 即使在停止使用AAS后,心功能也会持续下降.
- 使用AAS是举重运动员心脏功能受损的重要决定因素.
相关概念视频
01:20Exercise and Cardiovascular Response
826
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
826
01:29Pulmonary Tuberculosis I
245
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
245
01:28Disorders of the Skeletal Muscle
966
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
966
01:26Heart Failure Drugs: Inotropic Agents
596
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
596
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:22Heart Failure Drugs: β-Blockers
344
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
344